Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Genzyme’

Sanofi Genzyme launches multiple sclerosis awareness campaign

Sanofi Genzyme has launched a global initiative to raise awareness about the physical and emotional impact of multiple sclerosis (MS) on everyday life.

Bron: PMLiVE Meer lezen »

Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). The ongoing Phase II CAMMS223 study showed that, over 10 years of follow-up, 76% of patients were shown to be free from 6-month confirmed disability worsening.

Bron: InPharm.com Meer lezen »

Sanofi MS treatment slows brain atrophy in trial

Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) versus placebo over two years in people with relapsing multiple sclerosis (RMS).  

Bron: InPharm.com Meer lezen »

Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care

Genzyme, a Sanofi company, today announced a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. To better understand the full burden associated with RMS, Genzyme fielded a global survey among […]

Bron: World Pharma News Meer lezen »

Genzyme opts into gene silencing therapy for haemophilia

A collaboration between Sanofi’s Genzyme unit and Alnylam’s set up in 2014 has borne its first fruit, with Genzyme opting into a drug candidate for haemophilia. The drug – called ALN-AT3 – is an RNA interference (RNAi) drug that works via a process known as gene silencing, switching off the function of an endogenous protein […]

Bron: PMLiVE Meer lezen »

FDA grants breakthrough therapy designation to Genzyme’s Olipudase Alfa

Sanofi and its subsidiary Genzyme said on Thursday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to olipudase alfa.

Bron: Reuters Meer lezen »

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters. The Cambridge, Massachusetts company is confident in the commercial success of its two MS drugs Lemtrada and Aubagio and is “very active” in […]

Bron: Reuters Meer lezen »

Henri Termeer verruilt Genzyme voor Prosensa

De biofarmaceutische onderneming Prosensa heeft Henri Termeer, voormalig CEO van Genzyme, benoemd tot strategisch adviseur. Termeer zal Prosensa adviseren op het gebied van strategische vraagstukken en de groeiambities. Dat meldt Prosensa. Meer lezen »

  Meer lezen »

Discussie toekomst medicijnen bij zieken Pompe en Fabry

Minister Schippers gaat onderhandelen met de fabrikanten van de geneesmiddelen voor de ziekte van Fabry en de ziekte van Pompe. Dat meldt het NOS. Enkele dagen geleden adviseerde het College voor Zorgverzekeringen (CVZ) het kabinet nog de medicijnen voor de twee zeldzame ziektes niet meer te vergoeden vanwege de hoge kosten. Meer lezen »

  Meer lezen »

Genzyme niet verplicht om Ataluren aan patiëntjes met Duchenne te geven

Genzyme hoeft het middel Ataluren niet beschikbaar te stellen aan twee kinderen uit Veenendaal die aan de ziekte van Duchenne lijden. Dat heeft de rechtbank in Amsterdam bepaald in een kort geding dat de ouders hadden aangespannen. Meer lezen »

  Meer lezen »

« Oudere artikelen |